Industry Voices—The patent environment around IoT and blockchain is complex. Here's what medical device companies need to know

To avoid costly patent mistakes, a company must be aware of the patent landscape and potential infringement problems. (PanchenkoVladimir/Shutterstock)

There are several reasons medical device companies need to consider blockchain issues along with the internet of things. IoT will soon become a widespread technology, and it will require new levels of security and integrity in a healthcare setting.

Beyond the ability to track a device or ensure custody over the chain of title—all things that are easily done without blockchain—if you are working to get nearer to your end user by harnessing data, blockchain could be critical.

If your strategic plan includes reconfiguring your company’s vertical integration, you will likely benefit from blockchain applications. If you are moving beyond manufacturing and integrating products and services into healthcare solutions, blockchain can be a crucial differentiator and eventually a necessity for success.

Free Daily Newsletter

Like this story? Subscribe to FierceHealthcare!

The healthcare sector remains in flux as policy, regulation, technology and trends shape the market. FierceHealthcare subscribers rely on our suite of newsletters as their must-read source for the latest news, analysis and data impacting their world. Sign up today to get healthcare news and updates delivered to your inbox and read on the go.

Each of these strategies may be achieved by connected medical devices actively producing patient data within a larger connected environment. Ensuring the integrity of the device and the data it produces is critical for the success of these strategies. The device and the data must be protected against intentional hacking or unintentional errors.

RELATED: Accenture: AI, blockchain will have 'transformational' impact in next 3 years

The patent environment related to these two domains is already complicated and in a state of continued expansion. It will be years before consolidation and greater order comes to this environment. It is, therefore, advised that companies entering this environment with products and solutions have a coherent patent strategy in place.

In addition, protecting your own innovations related to IoT and blockchain will have critical implications for the implementation of your strategies. These technologies pose unique patent challenges. To achieve enforceable patents requires considered and current drafting tactics.

The patenting exercise in these domains is important due to the expected market size of IoT and blockchain. Most of the large tech players have been busy patenting in each of these technologies, and many newer companies have dedicated themselves to innovating in these technologies.

Also, there are already several non-practicing entities collecting patent assets in these technologies. The interest in these domains is global, and the patent landscape extends, in material ways, globally. This makes the patent landscape complex and fragmented.

To avoid costly patent mistakes, a company must be aware of the patent landscape and potential infringement problems. Licensing may be required for achieving certain product and solution manufacturing or sales.

RELATED: Industry Voices—Healthcare industries are underinvesting in AI patenting

Based on our research, we expect opportunities for licensing with some of the important patent holders including perhaps Qualcomm and LG. However, non-practicing entities must also be considered.

Many of the patent holders will be keen on exploiting their portfolios, thereby enabling them to extend their platforms as widely as possible. Investigating the patent landscape, along with the fit of the particular technologies being offered, is essential during the product/solution planning stage.

Early adopters may achieve certain benefits in their licensing efforts, because they might be granted greater rights in participating in or have some influence over the continued development of a platform’s technology. Those who wait may benefit from a clearer picture of the more widely used and successful IoT/blockchain platforms, thereby averting potentially costly mistakes.

Developing your own IP in these domains will likely be beneficial. There is no de facto platform yet, and there is still white space in the landscape for important innovations. Even less substantial innovations may play an important role in differentiating your product/solutions. At this stage, we suggest that each innovation you make in this area be closely scrutinized for patentability. Defensive patenting and IP bargaining chips may play an important role in any licensing negotiation or infringement litigation.

When patenting device innovations in these domains, one must consider the inherent interoperability of the IoT technology within a globally distributed blockchain network. This raises issues such as divided infringement, damages related to the entire market value and patent exhaustion. Specifications and patent claims must be drafted with great forethought and with the most current best practices.

We also suggest consideration of an international outlook for both your infringement/licensing analysis and your patenting program. Both the IoT and blockchain domains are global in scope, may not be dominated by U.S. entities and will not be controlled by U.S. regulations alone.

RELATED: Industry Voices—Why blockchain is the healthcare disrupter we’ve been waiting for

Europe and China must be considered, not only for regulatory, manufacturing and sales concerns but also for patent concerns in the U.S. Chinese companies intend on playing a major role in these domains and their patent filings in the U.S. will manifest that intent.

TAKEAWAY: As a medical device company developing new solutions, IoT and blockchain must be important components of your strategic planning. Patent implications should be considered early in your planning.

Philip Braginsky is co-chair of the Intellectual Property Group and co-chair of the Pharmaceutical and Biologics and China practices at Tarter Krinsky & Drogin, a midsize law firm in New York City. His experience includes intellectual property counseling, litigation and patent and trademark procurement in the life sciences, tech and financial industries.

Suggested Articles

A handful of major healthcare groups and vendors are throwing their weight behind ONC's information blocking proposal.

Rebates for Part D drugs grew from 2011 to 2015 but not enough to offset price spikes, a study found.

Medicare Advantage plans still have time to meet their year-end goals.